Mizolastine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Mizolastine
Accession Number
DB12523
Type
Small Molecule
Groups
Investigational
Description

Mizolastine is under investigation in clinical trial NCT01928316 (A Bioequivalence Study of Domestic (Made in China) and Imported Mizolastine Tablets in Healthy Volunteers).

Structure
Thumb
Synonyms
Not Available
Categories
UNII
244O1F90NA
CAS number
108612-45-9
Weight
Average: 432.503
Monoisotopic: 432.207387612
Chemical Formula
C24H25FN6O
InChI Key
PVLJETXTTWAYEW-UHFFFAOYSA-N
InChI
InChI=1S/C24H25FN6O/c1-29(23-26-13-10-22(32)28-23)19-11-14-30(15-12-19)24-27-20-4-2-3-5-21(20)31(24)16-17-6-8-18(25)9-7-17/h2-10,13,19H,11-12,14-16H2,1H3,(H,26,28,32)
IUPAC Name
2-[(1-{1-[(4-fluorophenyl)methyl]-1H-1,3-benzodiazol-2-yl}piperidin-4-yl)(methyl)amino]pyrimidin-4-ol
SMILES
CN(C1CCN(CC1)C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1)C1=NC=CC(O)=N1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
PathwayCategory
Mizolastine H1-Antihistamine ActionDrug action
Mizolastine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Mizolastine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Mizolastine.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Mizolastine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Mizolastine.Experimental, Illicit
AmphetamineAmphetamine may decrease the sedative activities of Mizolastine.Approved, Illicit, Investigational
BenzphetamineBenzphetamine may decrease the sedative activities of Mizolastine.Approved, Illicit
Benzylpenicilloyl PolylysineMizolastine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Mizolastine.Approved, Investigational
ChlorphentermineChlorphentermine may decrease the sedative activities of Mizolastine.Illicit, Withdrawn
DextroamphetamineDextroamphetamine may decrease the sedative activities of Mizolastine.Approved, Illicit
DiethylpropionDiethylpropion may decrease the sedative activities of Mizolastine.Approved, Illicit
GepefrineGepefrine may decrease the sedative activities of Mizolastine.Experimental
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Mizolastine.Approved, Investigational
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Mizolastine.Approved
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Mizolastine.Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Mizolastine.Approved, Investigational
MephedroneMephedrone may decrease the sedative activities of Mizolastine.Investigational
MephentermineMephentermine may decrease the sedative activities of Mizolastine.Approved
MethamphetamineMethamphetamine may decrease the sedative activities of Mizolastine.Approved, Illicit
MethoxyphenamineMethoxyphenamine may decrease the sedative activities of Mizolastine.Experimental
MidomafetamineMidomafetamine may decrease the sedative activities of Mizolastine.Experimental, Illicit, Investigational
MMDAMMDA may decrease the sedative activities of Mizolastine.Experimental, Illicit
PhenterminePhentermine may decrease the sedative activities of Mizolastine.Approved, Illicit
PseudoephedrinePseudoephedrine may decrease the sedative activities of Mizolastine.Approved
RitobegronRitobegron may decrease the sedative activities of Mizolastine.Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0240233
PubChem Compound
65906
PubChem Substance
347828752
ChemSpider
59315
BindingDB
22877
ChEBI
31857
ChEMBL
CHEMBL94454
PharmGKB
PA166129535
Wikipedia
Mizolastine
ATC Codes
R06AX25 — Mizolastine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHealthy Volunteers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.104 mg/mLALOGPS
logP4.63ALOGPS
logP5.11ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)12.24ChemAxon
pKa (Strongest Basic)5.93ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area70.31 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity123.45 m3·mol-1ChemAxon
Polarizability46.72 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0011900000-375df4a855e43dfec509
MS/MS Spectrum - , positiveLC-MS/MSsplash10-056s-1924000000-3222d3ee56cb73f00360
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001i-0721900000-53e1c9b1a9ae2a2a816d

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzimidazoles. These are organic compounds containing a benzene ring fused to an imidazole ring (five member ring containing a nitrogen atom, 4 carbon atoms, and two double bonds).
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzimidazoles
Sub Class
Not Available
Direct Parent
Benzimidazoles
Alternative Parents
Dialkylarylamines / Hydroxypyrimidines / Fluorobenzenes / Aminopyrimidines and derivatives / Piperidines / N-substituted imidazoles / Aryl fluorides / Aminoimidazoles / Heteroaromatic compounds / Azacyclic compounds
show 4 more
Substituents
Benzimidazole / Dialkylarylamine / Aminopyrimidine / Fluorobenzene / Hydroxypyrimidine / Halobenzene / Aminoimidazole / Aryl fluoride / Aryl halide / Monocyclic benzene moiety
show 17 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 16:42 / Updated on August 02, 2018 06:39